nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Cisplatin—bone cancer	0.0639	0.269	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—bone cancer	0.0428	0.181	CbGbCtD
Paroxetine—CYP2C9—Cisplatin—bone cancer	0.0338	0.142	CbGbCtD
Paroxetine—ABCB1—Cisplatin—bone cancer	0.0328	0.138	CbGbCtD
Paroxetine—ABCB1—Doxorubicin—bone cancer	0.022	0.0926	CbGbCtD
Paroxetine—ABCB1—Methotrexate—bone cancer	0.0213	0.0897	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—bone cancer	0.0207	0.0872	CbGbCtD
Paroxetine—TACR1—trigeminal nerve—bone cancer	0.0139	0.33	CbGeAlD
Paroxetine—TACR1—cranial nerve—bone cancer	0.0099	0.235	CbGeAlD
Paroxetine—HTR2A—trigeminal nerve—bone cancer	0.00339	0.0806	CbGeAlD
Paroxetine—HTR2A—cranial nerve—bone cancer	0.00241	0.0574	CbGeAlD
Paroxetine—HTR2A—vertebral column—bone cancer	0.00237	0.0563	CbGeAlD
Paroxetine—TACR1—connective tissue—bone cancer	0.00204	0.0486	CbGeAlD
Paroxetine—HTR2A—hindlimb—bone cancer	0.00203	0.0484	CbGeAlD
Paroxetine—HTR2A—appendage—bone cancer	0.00175	0.0415	CbGeAlD
Paroxetine—TACR1—spinal cord—bone cancer	0.00135	0.0322	CbGeAlD
Paroxetine—SLC6A3—spinal cord—bone cancer	0.000681	0.0162	CbGeAlD
Paroxetine—SLC6A4—spinal cord—bone cancer	0.000624	0.0148	CbGeAlD
Paroxetine—HTR2A—connective tissue—bone cancer	0.000498	0.0118	CbGeAlD
Paroxetine—Erythema multiforme—Methotrexate—bone cancer	0.000343	0.000588	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000343	0.000588	CcSEcCtD
Paroxetine—HTR2A—tendon—bone cancer	0.000342	0.00814	CbGeAlD
Paroxetine—Haemoglobin—Epirubicin—bone cancer	0.000341	0.000585	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—bone cancer	0.000341	0.000585	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—bone cancer	0.000341	0.000585	CcSEcCtD
Paroxetine—Rhinitis—Epirubicin—bone cancer	0.00034	0.000583	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—bone cancer	0.00034	0.000583	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—bone cancer	0.00034	0.000583	CcSEcCtD
Paroxetine—Haemorrhage—Epirubicin—bone cancer	0.000339	0.000582	CcSEcCtD
Paroxetine—Hepatitis—Epirubicin—bone cancer	0.000339	0.000582	CcSEcCtD
Paroxetine—Eye disorder—Methotrexate—bone cancer	0.000339	0.000581	CcSEcCtD
Paroxetine—Tinnitus—Methotrexate—bone cancer	0.000338	0.00058	CcSEcCtD
Paroxetine—Hypoaesthesia—Epirubicin—bone cancer	0.000338	0.000579	CcSEcCtD
Paroxetine—Asthenia—Cisplatin—bone cancer	0.000337	0.000577	CcSEcCtD
Paroxetine—Pharyngitis—Epirubicin—bone cancer	0.000337	0.000577	CcSEcCtD
Paroxetine—Cardiac disorder—Methotrexate—bone cancer	0.000337	0.000577	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—bone cancer	0.000335	0.000575	CcSEcCtD
Paroxetine—Oedema peripheral—Epirubicin—bone cancer	0.000334	0.000573	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—bone cancer	0.000334	0.000572	CcSEcCtD
Paroxetine—Connective tissue disorder—Epirubicin—bone cancer	0.000334	0.000572	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000331	0.000567	CcSEcCtD
Paroxetine—HTR2A—spinal cord—bone cancer	0.00033	0.00785	CbGeAlD
Paroxetine—Epistaxis—Doxorubicin—bone cancer	0.00033	0.000566	CcSEcCtD
Paroxetine—Angiopathy—Methotrexate—bone cancer	0.000329	0.000564	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—bone cancer	0.000328	0.000563	CcSEcCtD
Paroxetine—Immune system disorder—Methotrexate—bone cancer	0.000328	0.000562	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—bone cancer	0.000327	0.000561	CcSEcCtD
Paroxetine—Mediastinal disorder—Methotrexate—bone cancer	0.000327	0.00056	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—bone cancer	0.000326	0.00056	CcSEcCtD
Paroxetine—Chills—Methotrexate—bone cancer	0.000325	0.000558	CcSEcCtD
Paroxetine—Diarrhoea—Cisplatin—bone cancer	0.000321	0.000551	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—bone cancer	0.000321	0.00055	CcSEcCtD
Paroxetine—Alopecia—Methotrexate—bone cancer	0.000321	0.000549	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—bone cancer	0.00032	0.000548	CcSEcCtD
Paroxetine—Mental disorder—Methotrexate—bone cancer	0.000318	0.000545	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—bone cancer	0.000317	0.000544	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—bone cancer	0.000316	0.000542	CcSEcCtD
Paroxetine—Erythema—Methotrexate—bone cancer	0.000316	0.000541	CcSEcCtD
Paroxetine—Malnutrition—Methotrexate—bone cancer	0.000316	0.000541	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—bone cancer	0.000316	0.000541	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—bone cancer	0.000315	0.00054	CcSEcCtD
Paroxetine—Flushing—Epirubicin—bone cancer	0.000315	0.00054	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—bone cancer	0.000315	0.00054	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—bone cancer	0.000314	0.000538	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—bone cancer	0.000314	0.000538	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—bone cancer	0.000312	0.000536	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—bone cancer	0.000312	0.000534	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—bone cancer	0.000309	0.00053	CcSEcCtD
Paroxetine—Dysgeusia—Methotrexate—bone cancer	0.000309	0.00053	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—bone cancer	0.000309	0.000529	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—bone cancer	0.000308	0.000528	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—bone cancer	0.000307	0.000525	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—bone cancer	0.000306	0.000524	CcSEcCtD
Paroxetine—Back pain—Methotrexate—bone cancer	0.000305	0.000523	CcSEcCtD
Paroxetine—Chills—Epirubicin—bone cancer	0.000305	0.000522	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—bone cancer	0.000303	0.00052	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—bone cancer	0.000303	0.000519	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—bone cancer	0.0003	0.000514	CcSEcCtD
Paroxetine—Vomiting—Cisplatin—bone cancer	0.000299	0.000512	CcSEcCtD
Paroxetine—Vision blurred—Methotrexate—bone cancer	0.000298	0.00051	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—bone cancer	0.000297	0.00051	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—bone cancer	0.000297	0.000509	CcSEcCtD
Paroxetine—Rash—Cisplatin—bone cancer	0.000296	0.000507	CcSEcCtD
Paroxetine—Dermatitis—Cisplatin—bone cancer	0.000296	0.000507	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—bone cancer	0.000295	0.000506	CcSEcCtD
Paroxetine—Erythema—Epirubicin—bone cancer	0.000295	0.000506	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—bone cancer	0.000294	0.000503	CcSEcCtD
Paroxetine—Ill-defined disorder—Methotrexate—bone cancer	0.000293	0.000502	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—bone cancer	0.000293	0.000502	CcSEcCtD
Paroxetine—Anaemia—Methotrexate—bone cancer	0.000292	0.0005	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—bone cancer	0.000291	0.0005	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—bone cancer	0.000291	0.0005	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—bone cancer	0.000291	0.000499	CcSEcCtD
Paroxetine—Tension—Epirubicin—bone cancer	0.00029	0.000497	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—bone cancer	0.000289	0.000496	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—bone cancer	0.000287	0.000492	CcSEcCtD
Paroxetine—Back pain—Epirubicin—bone cancer	0.000286	0.00049	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—bone cancer	0.000285	0.000488	CcSEcCtD
Paroxetine—Malaise—Methotrexate—bone cancer	0.000285	0.000488	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—bone cancer	0.000284	0.000487	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—bone cancer	0.000284	0.000486	CcSEcCtD
Paroxetine—Vertigo—Methotrexate—bone cancer	0.000284	0.000486	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—bone cancer	0.000283	0.000485	CcSEcCtD
Paroxetine—Leukopenia—Methotrexate—bone cancer	0.000283	0.000484	CcSEcCtD
Paroxetine—Chills—Doxorubicin—bone cancer	0.000282	0.000483	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—bone cancer	0.000281	0.000481	CcSEcCtD
Paroxetine—Nausea—Cisplatin—bone cancer	0.000279	0.000478	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—bone cancer	0.000278	0.000477	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—bone cancer	0.000278	0.000476	CcSEcCtD
Paroxetine—Cough—Methotrexate—bone cancer	0.000276	0.000472	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—bone cancer	0.000275	0.000472	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—bone cancer	0.000274	0.00047	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—bone cancer	0.000274	0.000469	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—bone cancer	0.000273	0.000469	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—bone cancer	0.000273	0.000469	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—bone cancer	0.000273	0.000468	CcSEcCtD
Paroxetine—Agitation—Epirubicin—bone cancer	0.000272	0.000465	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—bone cancer	0.000269	0.000462	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—bone cancer	0.000269	0.000461	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—bone cancer	0.000269	0.000461	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—bone cancer	0.000269	0.000461	CcSEcCtD
Paroxetine—Tension—Doxorubicin—bone cancer	0.000268	0.00046	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—bone cancer	0.000268	0.000459	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000267	0.000458	CcSEcCtD
Paroxetine—Malaise—Epirubicin—bone cancer	0.000266	0.000457	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—bone cancer	0.000266	0.000455	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—bone cancer	0.000266	0.000455	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—bone cancer	0.000265	0.000455	CcSEcCtD
Paroxetine—Syncope—Epirubicin—bone cancer	0.000265	0.000454	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—bone cancer	0.000264	0.000453	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—bone cancer	0.000264	0.000453	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—bone cancer	0.000263	0.000451	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—bone cancer	0.000261	0.000448	CcSEcCtD
Paroxetine—Confusional state—Methotrexate—bone cancer	0.00026	0.000445	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—bone cancer	0.00026	0.000445	CcSEcCtD
Paroxetine—Cough—Epirubicin—bone cancer	0.000258	0.000442	CcSEcCtD
Paroxetine—Anaphylactic shock—Methotrexate—bone cancer	0.000258	0.000442	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—bone cancer	0.000258	0.000442	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—bone cancer	0.000256	0.000439	CcSEcCtD
Paroxetine—Infection—Methotrexate—bone cancer	0.000256	0.000439	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—bone cancer	0.000255	0.000437	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—bone cancer	0.000254	0.000435	CcSEcCtD
Paroxetine—Nervous system disorder—Methotrexate—bone cancer	0.000253	0.000433	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—bone cancer	0.000253	0.000433	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—bone cancer	0.000252	0.000432	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—bone cancer	0.000252	0.000431	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—bone cancer	0.000252	0.000431	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—bone cancer	0.000252	0.000431	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—bone cancer	0.000251	0.000431	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—bone cancer	0.000251	0.00043	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—bone cancer	0.00025	0.000429	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00025	0.000428	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—bone cancer	0.000249	0.000427	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—bone cancer	0.000249	0.000426	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—bone cancer	0.000247	0.000423	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—bone cancer	0.000246	0.000422	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—bone cancer	0.000246	0.000421	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—bone cancer	0.000245	0.00042	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—bone cancer	0.000245	0.000419	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—bone cancer	0.000243	0.000417	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—bone cancer	0.000242	0.000414	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—bone cancer	0.000241	0.000413	CcSEcCtD
Paroxetine—Oedema—Epirubicin—bone cancer	0.000241	0.000413	CcSEcCtD
Paroxetine—Hypotension—Methotrexate—bone cancer	0.000241	0.000413	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—bone cancer	0.00024	0.000412	CcSEcCtD
Paroxetine—Infection—Epirubicin—bone cancer	0.00024	0.000411	CcSEcCtD
Paroxetine—Cough—Doxorubicin—bone cancer	0.000239	0.000409	CcSEcCtD
Paroxetine—Shock—Epirubicin—bone cancer	0.000237	0.000407	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—bone cancer	0.000237	0.000406	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—bone cancer	0.000236	0.000405	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—bone cancer	0.000236	0.000405	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—bone cancer	0.000236	0.000405	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—bone cancer	0.000235	0.000403	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000235	0.000402	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—bone cancer	0.000234	0.000401	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—bone cancer	0.000233	0.0004	CcSEcCtD
Paroxetine—Insomnia—Methotrexate—bone cancer	0.000233	0.000399	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—bone cancer	0.000233	0.000399	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—bone cancer	0.000233	0.000399	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—bone cancer	0.000233	0.000399	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—bone cancer	0.000232	0.000398	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—bone cancer	0.000231	0.000397	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000231	0.000396	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—bone cancer	0.00023	0.000394	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—bone cancer	0.00023	0.000394	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—bone cancer	0.000229	0.000393	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—bone cancer	0.000228	0.00039	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—bone cancer	0.000227	0.000389	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—bone cancer	0.000225	0.000386	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—bone cancer	0.000225	0.000386	CcSEcCtD
Paroxetine—Decreased appetite—Methotrexate—bone cancer	0.000224	0.000384	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—bone cancer	0.000223	0.000382	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—bone cancer	0.000223	0.000382	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000222	0.000381	CcSEcCtD
Paroxetine—Fatigue—Methotrexate—bone cancer	0.000222	0.000381	CcSEcCtD
Paroxetine—Infection—Doxorubicin—bone cancer	0.000222	0.00038	CcSEcCtD
Paroxetine—Pain—Methotrexate—bone cancer	0.00022	0.000378	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00022	0.000377	CcSEcCtD
Paroxetine—Shock—Doxorubicin—bone cancer	0.00022	0.000376	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—bone cancer	0.000219	0.000375	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—bone cancer	0.000218	0.000374	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—bone cancer	0.000218	0.000374	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—bone cancer	0.000218	0.000373	CcSEcCtD
Paroxetine—ABCB1—bone marrow—bone cancer	0.000217	0.00517	CbGeAlD
Paroxetine—Skin disorder—Doxorubicin—bone cancer	0.000217	0.000371	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—bone cancer	0.000217	0.000371	CcSEcCtD
Paroxetine—ABCB1—spinal cord—bone cancer	0.000216	0.00515	CbGeAlD
Paroxetine—Hyperhidrosis—Doxorubicin—bone cancer	0.000216	0.00037	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—bone cancer	0.000215	0.000369	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—bone cancer	0.000214	0.000367	CcSEcCtD
Paroxetine—Feeling abnormal—Methotrexate—bone cancer	0.000212	0.000364	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—bone cancer	0.000212	0.000364	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—bone cancer	0.000211	0.000361	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—bone cancer	0.00021	0.000359	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—bone cancer	0.000209	0.000357	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000208	0.000357	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—bone cancer	0.000208	0.000356	CcSEcCtD
Paroxetine—Pain—Epirubicin—bone cancer	0.000206	0.000353	CcSEcCtD
Paroxetine—Constipation—Epirubicin—bone cancer	0.000206	0.000353	CcSEcCtD
Paroxetine—Urticaria—Methotrexate—bone cancer	0.000205	0.000351	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—bone cancer	0.000204	0.000349	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—bone cancer	0.000204	0.000349	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000203	0.000348	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—bone cancer	0.000202	0.000346	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—bone cancer	0.0002	0.000343	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—bone cancer	0.000199	0.000341	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—bone cancer	0.000199	0.000341	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—bone cancer	0.000198	0.00034	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—bone cancer	0.000197	0.000338	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—bone cancer	0.000196	0.000337	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—bone cancer	0.000194	0.000332	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000193	0.00033	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—bone cancer	0.000192	0.00033	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—bone cancer	0.000192	0.000328	CcSEcCtD
Paroxetine—Pain—Doxorubicin—bone cancer	0.000191	0.000327	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—bone cancer	0.000191	0.000327	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—bone cancer	0.000191	0.000327	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—bone cancer	0.000191	0.000327	CcSEcCtD
Paroxetine—Hypersensitivity—Methotrexate—bone cancer	0.00019	0.000325	CcSEcCtD
Paroxetine—Asthenia—Methotrexate—bone cancer	0.000185	0.000317	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—bone cancer	0.000184	0.000315	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000182	0.000313	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—bone cancer	0.000182	0.000312	CcSEcCtD
Paroxetine—Hypersensitivity—Epirubicin—bone cancer	0.000178	0.000305	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—bone cancer	0.000177	0.000304	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—bone cancer	0.000176	0.000302	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—bone cancer	0.000176	0.000302	CcSEcCtD
Paroxetine—Diarrhoea—Methotrexate—bone cancer	0.000176	0.000302	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—bone cancer	0.000173	0.000297	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—bone cancer	0.000171	0.000292	CcSEcCtD
Paroxetine—Dizziness—Methotrexate—bone cancer	0.00017	0.000292	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—bone cancer	0.000165	0.000283	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—bone cancer	0.000164	0.000282	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—bone cancer	0.000164	0.000281	CcSEcCtD
Paroxetine—Rash—Methotrexate—bone cancer	0.000162	0.000278	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—bone cancer	0.000162	0.000278	CcSEcCtD
Paroxetine—Headache—Methotrexate—bone cancer	0.000161	0.000277	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—bone cancer	0.00016	0.000274	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—bone cancer	0.000159	0.000273	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—bone cancer	0.000158	0.000271	CcSEcCtD
Paroxetine—CHRM1—Circadian rythm related genes—CDK4—bone cancer	0.000157	0.00114	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000156	0.00113	CbGpPWpGaD
Paroxetine—Vomiting—Epirubicin—bone cancer	0.000153	0.000263	CcSEcCtD
Paroxetine—Nausea—Methotrexate—bone cancer	0.000153	0.000262	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—bone cancer	0.000153	0.000262	CcSEcCtD
Paroxetine—Rash—Epirubicin—bone cancer	0.000152	0.000261	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—bone cancer	0.000152	0.00026	CcSEcCtD
Paroxetine—HTR2A—GPCR downstream signaling—RGS1—bone cancer	0.000152	0.0011	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GRM4—bone cancer	0.000152	0.0011	CbGpPWpGaD
Paroxetine—Headache—Epirubicin—bone cancer	0.000151	0.000259	CcSEcCtD
Paroxetine—CHRM1—GPCR downstream signaling—GRM4—bone cancer	0.000151	0.0011	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—RGS1—bone cancer	0.000151	0.0011	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—RGS1—bone cancer	0.00015	0.00109	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GRM4—bone cancer	0.00015	0.00109	CbGpPWpGaD
Paroxetine—CHRM4—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.00015	0.00109	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—RGS1—bone cancer	0.000149	0.00108	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GRM4—bone cancer	0.000149	0.00108	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000149	0.00108	CbGpPWpGaD
Paroxetine—Dizziness—Doxorubicin—bone cancer	0.000148	0.000253	CcSEcCtD
Paroxetine—CYP2B6—Metabolism—NDUFA12—bone cancer	0.000147	0.00107	CbGpPWpGaD
Paroxetine—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000146	0.00106	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—GNA11—bone cancer	0.000146	0.00106	CbGpPWpGaD
Paroxetine—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000145	0.00105	CbGpPWpGaD
Paroxetine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000144	0.00105	CbGpPWpGaD
Paroxetine—CHRM5—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000143	0.00104	CbGpPWpGaD
Paroxetine—Nausea—Epirubicin—bone cancer	0.000143	0.000246	CcSEcCtD
Paroxetine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000143	0.00104	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NT5C3A—bone cancer	0.000142	0.00103	CbGpPWpGaD
Paroxetine—Vomiting—Doxorubicin—bone cancer	0.000142	0.000243	CcSEcCtD
Paroxetine—Rash—Doxorubicin—bone cancer	0.000141	0.000241	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—bone cancer	0.000141	0.000241	CcSEcCtD
Paroxetine—Headache—Doxorubicin—bone cancer	0.00014	0.00024	CcSEcCtD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000139	0.00101	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000139	0.00101	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GRM4—bone cancer	0.000138	0.001	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—RGS1—bone cancer	0.000138	0.001	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—RGS1—bone cancer	0.000137	0.000997	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GRM4—bone cancer	0.000137	0.000997	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—RGS1—bone cancer	0.000137	0.000994	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GRM4—bone cancer	0.000137	0.000994	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—BRAF—bone cancer	0.000136	0.000989	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—ATF1—bone cancer	0.000136	0.000988	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—RGS1—bone cancer	0.000135	0.000984	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GRM4—bone cancer	0.000135	0.000984	CbGpPWpGaD
Paroxetine—Nausea—Doxorubicin—bone cancer	0.000133	0.000227	CcSEcCtD
Paroxetine—TACR1—Signaling Pathways—IL3—bone cancer	0.000132	0.000963	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GRM1—bone cancer	0.000132	0.000957	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GRM1—bone cancer	0.000131	0.000952	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GRM1—bone cancer	0.00013	0.000949	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GRM1—bone cancer	0.000129	0.00094	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—GNA11—bone cancer	0.000125	0.00091	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NDUFA12—bone cancer	0.000125	0.000908	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000125	0.000906	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—SMO—bone cancer	0.000124	0.000903	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000122	0.000889	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NT5C3A—bone cancer	0.000122	0.000888	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GRM4—bone cancer	0.00012	0.000873	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RGS1—bone cancer	0.00012	0.000873	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00012	0.000873	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—GNA11—bone cancer	0.00012	0.000871	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GRM1—bone cancer	0.000119	0.000869	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—SMO—bone cancer	0.000119	0.000865	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GRM1—bone cancer	0.000119	0.000864	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GRM1—bone cancer	0.000118	0.000862	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GRM1—bone cancer	0.000117	0.000853	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GRM4—bone cancer	0.000115	0.000836	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RGS1—bone cancer	0.000115	0.000836	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—MDM2—bone cancer	0.000114	0.000828	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—GNA11—bone cancer	0.000114	0.000826	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—IL3—bone cancer	0.000113	0.000825	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TGFBR2—bone cancer	0.000113	0.000824	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—TP53—bone cancer	0.000111	0.000811	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—GNA11—bone cancer	0.000109	0.000791	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NDUFA12—bone cancer	0.000109	0.000791	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—IL3—bone cancer	0.000109	0.00079	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000107	0.000778	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IGF1R—bone cancer	0.000107	0.000775	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GRM1—bone cancer	0.000104	0.000757	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000103	0.000752	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NT5C3A—bone cancer	0.000103	0.000752	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL3—bone cancer	0.000103	0.000749	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000102	0.000745	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000102	0.000739	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—JUN—bone cancer	0.000101	0.000736	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000101	0.000735	CbGpPWpGaD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000101	0.000733	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	9.97e-05	0.000725	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GRM1—bone cancer	9.97e-05	0.000725	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL3—bone cancer	9.86e-05	0.000717	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NT5C3A—bone cancer	9.01e-05	0.000655	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NT5C3A—bone cancer	8.49e-05	0.000618	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GNA11—bone cancer	8.47e-05	0.000617	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GNA11—bone cancer	8.43e-05	0.000613	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—SMO—bone cancer	8.41e-05	0.000612	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NT5C3A—bone cancer	8.41e-05	0.000612	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GNA11—bone cancer	8.4e-05	0.000611	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—SMO—bone cancer	8.37e-05	0.000609	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—SMO—bone cancer	8.34e-05	0.000607	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GNA11—bone cancer	8.32e-05	0.000605	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—SMO—bone cancer	8.26e-05	0.000601	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GRM4—bone cancer	8.14e-05	0.000592	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RGS1—bone cancer	8.14e-05	0.000592	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GRM4—bone cancer	8.09e-05	0.000589	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RGS1—bone cancer	8.09e-05	0.000589	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GRM4—bone cancer	8.07e-05	0.000587	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RGS1—bone cancer	8.07e-05	0.000587	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GRM4—bone cancer	7.99e-05	0.000581	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RGS1—bone cancer	7.99e-05	0.000581	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—KIT—bone cancer	7.73e-05	0.000562	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GNA11—bone cancer	7.7e-05	0.00056	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—IL3—bone cancer	7.68e-05	0.000559	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	7.66e-05	0.000558	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GNA11—bone cancer	7.65e-05	0.000557	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL3—bone cancer	7.64e-05	0.000556	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GNA11—bone cancer	7.63e-05	0.000555	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL3—bone cancer	7.62e-05	0.000554	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.57e-05	0.000551	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GNA11—bone cancer	7.56e-05	0.00055	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL3—bone cancer	7.54e-05	0.000549	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.53e-05	0.000548	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.51e-05	0.000546	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	7.39e-05	0.000538	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SMO—bone cancer	7.33e-05	0.000533	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—BRAF—bone cancer	7.26e-05	0.000529	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GRM1—bone cancer	7.06e-05	0.000513	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—EGFR—bone cancer	7.04e-05	0.000512	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SMO—bone cancer	7.02e-05	0.000511	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GRM1—bone cancer	7.02e-05	0.000511	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GRM1—bone cancer	7e-05	0.000509	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL3—bone cancer	6.98e-05	0.000508	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL3—bone cancer	6.94e-05	0.000505	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GRM1—bone cancer	6.93e-05	0.000504	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL3—bone cancer	6.92e-05	0.000503	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL3—bone cancer	6.85e-05	0.000498	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNA11—bone cancer	6.71e-05	0.000488	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—bone cancer	6.67e-05	0.000486	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	6.66e-05	0.000485	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNA11—bone cancer	6.42e-05	0.000467	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ATF1—bone cancer	6.23e-05	0.000454	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ENO2—bone cancer	6.22e-05	0.000452	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MDM2—bone cancer	6.09e-05	0.000443	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL3—bone cancer	6.08e-05	0.000442	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ATF1—bone cancer	5.97e-05	0.000434	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL3—bone cancer	5.82e-05	0.000424	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—DHFR—bone cancer	5.77e-05	0.00042	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNA11—bone cancer	5.39e-05	0.000392	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ENO2—bone cancer	5.35e-05	0.000389	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—JUN—bone cancer	5.29e-05	0.000385	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.24e-05	0.000381	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFBR2—bone cancer	5.2e-05	0.000378	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MMP9—bone cancer	5.15e-05	0.000374	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFBR2—bone cancer	4.98e-05	0.000362	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SMO—bone cancer	4.97e-05	0.000362	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—DHFR—bone cancer	4.96e-05	0.000361	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SMO—bone cancer	4.94e-05	0.00036	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SMO—bone cancer	4.93e-05	0.000359	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1R—bone cancer	4.89e-05	0.000356	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP3A4—bone cancer	4.89e-05	0.000356	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SMO—bone cancer	4.88e-05	0.000355	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1R—bone cancer	4.69e-05	0.000341	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNA11—bone cancer	4.64e-05	0.000337	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNA11—bone cancer	4.55e-05	0.000331	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ENO2—bone cancer	4.53e-05	0.000329	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNA11—bone cancer	4.52e-05	0.000329	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNA11—bone cancer	4.51e-05	0.000328	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNA11—bone cancer	4.46e-05	0.000325	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.4e-05	0.00032	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ATF1—bone cancer	4.23e-05	0.000308	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP3A4—bone cancer	4.2e-05	0.000306	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ATF1—bone cancer	4.2e-05	0.000306	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—DHFR—bone cancer	4.2e-05	0.000306	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ATF1—bone cancer	4.19e-05	0.000305	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTP1—bone cancer	4.18e-05	0.000304	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EGFR—bone cancer	4.16e-05	0.000303	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ATF1—bone cancer	4.15e-05	0.000302	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL3—bone cancer	4.12e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL3—bone cancer	4.1e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL3—bone cancer	4.09e-05	0.000297	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL3—bone cancer	4.05e-05	0.000294	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ENO2—bone cancer	3.94e-05	0.000287	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GNA11—bone cancer	3.93e-05	0.000286	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ENO2—bone cancer	3.72e-05	0.00027	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ENO2—bone cancer	3.69e-05	0.000268	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—DHFR—bone cancer	3.66e-05	0.000266	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTP1—bone cancer	3.6e-05	0.000262	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP3A4—bone cancer	3.56e-05	0.000259	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KIT—bone cancer	3.55e-05	0.000258	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.54e-05	0.000258	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFBR2—bone cancer	3.53e-05	0.000256	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFBR2—bone cancer	3.51e-05	0.000255	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFBR2—bone cancer	3.5e-05	0.000254	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—bone cancer	3.49e-05	0.000254	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFBR2—bone cancer	3.46e-05	0.000252	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—DHFR—bone cancer	3.45e-05	0.000251	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNA11—bone cancer	3.42e-05	0.000249	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—DHFR—bone cancer	3.42e-05	0.000249	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KIT—bone cancer	3.4e-05	0.000247	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—BRAF—bone cancer	3.34e-05	0.000243	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1R—bone cancer	3.32e-05	0.000241	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1R—bone cancer	3.3e-05	0.00024	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1R—bone cancer	3.29e-05	0.000239	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1R—bone cancer	3.26e-05	0.000237	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—EGFR—bone cancer	3.23e-05	0.000235	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNA11—bone cancer	3.22e-05	0.000235	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNA11—bone cancer	3.2e-05	0.000232	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—BRAF—bone cancer	3.19e-05	0.000232	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP3A4—bone cancer	3.1e-05	0.000226	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—EGFR—bone cancer	3.1e-05	0.000225	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTP1—bone cancer	3.04e-05	0.000221	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP3A4—bone cancer	2.92e-05	0.000213	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP3A4—bone cancer	2.9e-05	0.000211	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.88e-05	0.00021	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MDM2—bone cancer	2.79e-05	0.000203	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MDM2—bone cancer	2.68e-05	0.000195	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTP1—bone cancer	2.65e-05	0.000193	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—bone cancer	2.5e-05	0.000182	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—bone cancer	2.48e-05	0.00018	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—JUN—bone cancer	2.43e-05	0.000177	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KIT—bone cancer	2.41e-05	0.000175	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KIT—bone cancer	2.39e-05	0.000174	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KIT—bone cancer	2.38e-05	0.000174	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—bone cancer	2.36e-05	0.000172	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KIT—bone cancer	2.36e-05	0.000172	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—JUN—bone cancer	2.33e-05	0.000169	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—bone cancer	2.26e-05	0.000165	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—bone cancer	2.26e-05	0.000165	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—bone cancer	2.25e-05	0.000164	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—bone cancer	2.24e-05	0.000163	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—bone cancer	2.22e-05	0.000162	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—bone cancer	2.19e-05	0.000159	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—bone cancer	2.18e-05	0.000159	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—bone cancer	2.17e-05	0.000158	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—bone cancer	2.17e-05	0.000158	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—bone cancer	2.15e-05	0.000157	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—bone cancer	1.91e-05	0.000139	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MDM2—bone cancer	1.89e-05	0.000138	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MDM2—bone cancer	1.88e-05	0.000137	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MDM2—bone cancer	1.88e-05	0.000137	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—bone cancer	1.86e-05	0.000136	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MDM2—bone cancer	1.86e-05	0.000135	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—bone cancer	1.83e-05	0.000133	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JUN—bone cancer	1.65e-05	0.00012	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JUN—bone cancer	1.64e-05	0.000119	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JUN—bone cancer	1.63e-05	0.000119	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JUN—bone cancer	1.62e-05	0.000118	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—bone cancer	1.6e-05	0.000117	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—bone cancer	1.6e-05	0.000117	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—bone cancer	1.59e-05	0.000116	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—bone cancer	1.59e-05	0.000116	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—bone cancer	1.58e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—bone cancer	1.57e-05	0.000114	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—bone cancer	1.54e-05	0.000112	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—bone cancer	1.37e-05	0.0001	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—bone cancer	1.29e-05	9.42e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—bone cancer	1.29e-05	9.42e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—bone cancer	1.29e-05	9.37e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—bone cancer	1.28e-05	9.34e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—bone cancer	1.28e-05	9.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—bone cancer	1.27e-05	9.25e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—bone cancer	1.09e-05	7.91e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—bone cancer	1.08e-05	7.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—bone cancer	1.08e-05	7.84e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—bone cancer	1.07e-05	7.76e-05	CbGpPWpGaD
